Bridging the Gap: Index Volume [International Conference on AIDS (12th: 1998: Geneva, Switzerland)]

12th World AIDS Conference

positives *pregnancy 151

- Keyword Abstract -
habilitation of HIV/AIDS /Counselling, care and rehabilita 42459
Amis" (CDA), RCI/HIV commitment in prevention of HI 43323
geria provide integrated post-absortion care and STD manageme 13474
rmulation of policies in post-complex emergency conditions: The 44236
d infectious diseases in emergency conditions: The 60910
del feasibility program/ Post-exposure prevention (PEP) followin 249*/33172
ce in a London hospital/ prophylaxis for occupation 247*/33176
ersies in San Francisco/ prophylaxis: Community c 251*/33179
evention interventions/ prophylaxis for sexual risk 33184
ween husband and wife/ prophylaxis and sexual HI 33189
odeficiency virus (HIV) post-exposure prophylaxis/Preventability 23330
are workers (HCWs) as prophylaxis (PEP) for occu 246*/33171
dividuals presenting for prophylaxis (PEP) followin 33173
s (HCW)/Combination prophylaxis (PEP): A pros 33175
cacy of an out-of-house prophylaxis team for occu 33181
ealth impact of offering prophylaxis (PEP) for epis 576*/33183
ne)/National clinicians' prophylaxis hotline (PEPLi 33185
exposure/Feasibility of prevention research amon 33186
about non-occupational prophylaxis (PEP)/French 248*/33192
sk for HIV infection and chemoprophylaxis in a hos 33194
ontinuous coverage for prophylaxis in an urban un 60200
ommunity level-pre and post-HIV-test counselling multisector strat 60573
on for incarcerated and post-incarcerated women drug users/Re 43401
r HIV-infected patients/ Post-insertion complications of maxillary i 60462
nce and seroincidence: Post-intervention risk behavior changes/ 23206
e pooled analysis/Late post-natal mother-to-child transmission (L 456*/23266
ng for the prevention of transmission of HIV in an urban 316*/24124
mother to infant/Pre and HIV/STDs prevention from mot 60070
g HIV-1 perinatally and post-natally infected Kenyan children/Ch 60790
n HIV-infected women/ Post-operative complications following 19 13391
RT after sexual assault/ Post-sexual exposure prophylaxis (PSEP) 250*/33174
s/Inadequate pre- and post-test counselling for HIV in two South 24340
ith attendance at HIV counselling in Ethiopia/Factors 33280
nsfusions/Incidence of post-transfusion HIV (PT-HIV) in patients 42464
ent-situation analysis/ Poverty and the role of men and women in 43102
of HIV among refugees/ reduction to combat the spread of 44229
nce of STDs/HIV/AIDS/ and ignorance as principal factors 60757
udy/Work, income and poverty among people with HIV and AIDS 13336
ren affected by AIDS in stricken area/Playing again: Psyc 13377
olence in the context of on women's risk of infection in the 23466
ex workers as lending to alleviation/Rehabilitation of com 34260
rograms should include alleviation interventions/HIV/AID 44226
urvival/Advocacy for alleviation as an alternative tool to 44228
HIV, injection drug use, and nutrition in a downtown comm 44289
rehabilitation services/ Pozfit, positively fit: A prospective, pilot pro 504*/42400
ovirus (CMV)-PCR and pp-65 for the detection of CMV-disease in 22241
+ subjects/Effects of a PPD-pentavalent V3 loop penta-peptide c 21209
ess of anergy panel and PPD to diagnose tuberculosis (TB) infectio 13257
erculosis/Follow-up of skin test and cellular immune respons 31207
d AIDS control project ( PPLS )/The Multi-sectorial approach throu 44254
n of Vacutainer~ Brand PPTTM plasma preparation tubes for HIV vir 41138
sma preparation tubes ( ) during overnight shipment/Stability 60731
The traditional medical practitioners HIV/AIDS training and supp 13417
care to private medical in Tamil Nadu, South India/I 13475
es of allopathic general in the provision of STD servi 33243
powering rural medical in early diagnosis and syndr 33410
th AIDS, by traditional,on seeking modern treatme 34129
rs among drug users in Prague, Czech Republic 1996-1997/High 23197
test power in the world/ Prayer and love: The greatest power in the 60020
Outreach counselling by pre-adolescents /Outreach counselling b 33361
navir/ritonavir therapy/ Pre-existent mutations of the HIV proteas 32294
nd immunogenicity of pre-exposure rabies immunization in HIV- 32449
n Guadalajara, Mexico/ Pre-malignant cervical lesions (PCL) in HI 60396
egy for HIV/AIDS/STD/ Pre-marital sex counselling as a preventiv 60226
vs. d4T+RTV+SQV) in pre-treated patients/Preliminary data of a 60791
hods and HIV/STD risk/ Preaching to the choir: Preference for fem 14147
ully in a urban marginal precary area of Guatemala/The STD/HIV/ 43202
mpliance with universal precautions /Nursing care for persons wit 62*/22459
7/Practice of universal in health care workers in Thai 23345
Bs seroconversion of a precore hepatitis B virus mutant infection 32118
ount falls below 200/pl/ Predictive value of viral load and other ma 12133
ts in the era of HAART/ value of cytomegalovirus (CMV 22241
NSL) in AIDS patients/ value of thallium-201 SPECT in 22291

nd sensory neuropathy/ markers for HIV-associated de 560*/32191
t, France, 1985-1997/ value of weight loss > 10% and 42342
h active CMV disease/ value of CMV antigenemia for r 60191
n: Levels of MIP-1/ are predictive to the risk of HIV disease progr 13305
tuberculous (STB) as a factor of a HIV infection/The se 22161
nse to amikacin therapy of MAC infection?/ls a respons 22173
CMV)-Antigenemia as and follow-up marker of CMV re 22251

Keyword Abstract
brospinal fluid (CSF) as value of primary cerebral lymph 22324
/M184V mutation is not of therapeutic failure to d4T/3T 32310
ptase (RT) gene and its value at the start of antiretrovira 32311
h risk behaviors are not of anti-retroviral non-adherenc 32372
s of the time dependent value of HIV load and host gene 42146
dinavir (IDV) are highly of virological treatment failure i 42275
ility of progression and predictivity of immunological and virologi 13351
mbination treatment as predictor of response and guidance for tre 12300
S)/Serum albumin as a of survival in HIV infected (HIV+) 13309
e plasma viral load as a of virologic response to triple the 22359
-1 infected patients as of treatment failure in high acting 233*/32282
ion/Herpes zoster as a of HIV infection/Herpes zoster a 42127
um y-globulin level as a of HIV infection in perinatally exp 42399
um y-globulin level as a of HIV infection in perinatally exp 42407
V/ddl vs ZDV/ddl/NVP/ Predictors of duration of virologic suppres 12365
anese college students/ of condom use intention to prev 14155
ospective clinic cohort/ of success of antiretroviral ther 22363
sion in clinical practice/ of maximal viral suppression in 22387
ngage in sex with men/ of high-risk sexual behavior in 23122
n Budapest, Hungary/ of consistent condom use amo 23542
d activation in HIV risk: of sexual and drug abuse beha 24152
sers affected by HIV/ of satisfaction with informal car 24163
users: The SAIL study/ of depression in lower class inj 24227
combination therapies/ of non adherence to HIV combi 32375
n a street youth cohort/ of drug injection initiation in a st 33389
s - A longitudinal study/ of dropout and burnout in volun 34330
t indeterminate results/ of HIV infection among profess 41109
tor nelfinavir mesylate/ of response to treatment of HIV 41191
Itisite interview project/ for not currently receiving prote 413*/42282
I study of HIV+ women/ of combination antiretroviral th 42311
r HIV status-unknown/ of serostatus disclosure by HIV 60193
Affairs Medical Center/ of resource utilization in HIV/AI 60341
opportunistic infection/ of progression of the human im 60360
ong homeless women/ of mental distress and poor phy 60583
n HIV-infected patients/ of long-term virological and im 60703
omen will take risks? of lack of contraceptive use on f 60788
n HIV infected patients/ of viral load response in triple t 60805
y the use of progression predictors /Two antiretroviral drugs regim 12182
nd neuropsychological of mortality and disease progre 595*/13345
LTNP): Prevalence and through 18 years of follow-up/L 190*/13347
roups/Theory based of condom use intention and be 14163
elopments/Rates and of HIV risk behaviors among mi 14192
osis: analysis of clinical and molecular epidemiologic a 22137
d cohort/Incidence and of virologic failure of antiretrovir 22349
herapy (HAART) and of undetectable plasma viral lo 22365
n cities, USA/HIV and of unprotected receptive anal i 23120
SA/Prevalence and of unprotected receptive anal i 23139
site seroprevalence as of risk behaviors in a multi-site 23194
nd symptomatology as of HIV risk behaviors in adults 23531
n and CD4 cell count as of quality of life in HIV-positive 24223
/Skin manifestations as of HIV infection in Malawi/Skin 32272
t study/HIV genotypic of antiviral response to saquina 229*/32287
des and knowledge as /Adherence to protease inhibito 32337
I therapy/Evaluation of of adherence in HIV-infected p 32351
ional samples: Trends,, and validity/Perceptions of co 33427
nd body mass index as of survival after AIDS diagnosis 42360
ional samples: Trends,, and validity/Perceptions of ris 43122
s/Time-dependence of of death in HIV-infected patient 43468

M): A community study/ Predisposing risk factors for methamphet
IV-infected patients ( Predivir Cohort): Value of different CMV bl
SM, STD patients, and pregnancies in Slovenia/Unlinked anony
e measures in full-term /Mother-to-child transmissio
cidence and outcome of in HIV-Infected women/Incid
nd 1996/Incidence of in HIV-infected women betw
women living with AIDS/ Pregnancy intentions and decisions of Afri
dy of 364 HIV+ women/ outcomes in HIV+ women: A 4
of HIV infected women/ decision making in a well-moti

14217
22248
13189
23301
24194
24200
24195
32133
60372

ubtypes derived during pregnancy
al HIV-1 disease during
cleoside analog during
ginal HIV-1 DNA during
tection for HIV/STI and
choice of HIV testing in
yphilis prevalence in
rdance of HIV-1 among
al of STD control during
on/Antiretroviral use in
idovudine (ZDV) and
is provoking increased
social impact of HIV and

/Co-receptor usage of HIV-1 is 211*/11167
/Control of maternal HIV-1 dise 459*/12151
/Combination therapy with nevi 463*/12152
/HIV-1 subtype and shedding o 13117
prevention in Zimbabwe/Prom 13562
/Developing a training initiative 13566
and in STD syndromes among 22190
women in Nairobi, Kenya/Ser 23153
in Rakai, Uganda: Impact on m 528*/23276
in PACTG 316: A phase III ran 23281
termination among HIV-infecte 23321
incidence in women living with 24199
/The psychosocial impact of HI 24237